Provectus Biopharmaceuticals
PVCT · OTC
$0.0499+$0.001 (+2.04%)TodayMarket closed ·
Prev close $0.0489
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 30.0% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q3 FY24 | $0.00 | $0.00 | +0.0% |
| Q3 FY23 | $0.00 | $0.00 | +0.0% |
| Q4 FY12 | -$0.0306 | -$0.02 | +34.6% |
| Q3 FY12 | -$0.0306 | -$0.02 | +34.6% |
| Q2 FY12 | -$0.0357 | -$0.03 | +16.0% |
| Q1 FY12 | -$0.034 | -$0.04 | −17.6% |
| Q2 FY11 | -$0.0612 | -$0.04 | +34.6% |
| Q1 FY11 | -$0.034 | -$0.05 | −47.1% |
Earnings calls
- Shareholder/Analyst Call - Provectus Biopharmaceuticals, Inc.
- Shareholder/Analyst Call - Provectus Biopharmaceuticals, Inc.
- PVCT - Earnings call Q4 2024
- Earnings call Q3 2016
- Earnings call Q2 2016
- Earnings call Q1 2016
- Provectus Biopharmaceuticals' (PVCT) CEO Peter Culpepper on Q4 and 2015 Year-End Financial Business Update Call
- Earnings call Q4 2015
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.